+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying treatments for advanced solid tumors, which are cancers that have spread and often become resistant to existing therapies. This trial evaluates the safety, tolerability, how the body processes Mocertatug Rezetecan Mo-Rez, and its effectiveness when combined with other cancer medicines. Participants include adults with advanced solid tumors who have not responded to standard treatments, cannot tolerate them, or lack effective options. Participants will receive Mo-Rez intravenously, combined either with Dostarlimab for endometrial cancer or with Bevacizumab for ovarian cancer. The study is randomized, with multiple treatment groups, and includes two parts Part A focusing on dose-limiting toxicities and safety over about 7 to 22 months, and Part B assessing confirmed tumor response and survival outcomes up to approximately 37 months. During the trial, participants undergo regular evaluations including tumor assessments by RECIST criteria, biomarker analyses from tumor tissue samples, vital sign monitoring, lab tests, and ECGs. Researchers track adverse events, immune responses, drug concentrations, and quality of life measures. The study lasts up to nearly three years with ongoing safety and efficacy monitoring throughout.

Age: 18Years +All GendersPhase 1Phase 2
83 locations
E

Actively Recruiting

Researchers are evaluating a new medicine called Risvutatug Rezetecan also known as GSK5764227 in participants worldwide who have advanced gastrointestinal cancers that cannot be surgically removed. This study focuses on participants who have already received prior treatment and aims to assess how well the medicine works, how safe it is, and how the body processes it. It is a Phase 1b2, multicenter, open-label trial sponsored by GlaxoSmithKline. Participants will receive Risvutatug Rezetecan alone or in combination with other treatments. Multiple dosing groups exist, including different doses tailored to colon, rectum, and pancreatic cancer cohorts. The study uses a randomized, parallel design to compare these groups. Treatments are given according to assigned doses, and the trial monitors participants for up to approximately 37 months to assess response and safety. During the study, participants will undergo regular assessments including scans, blood tests, vital signs, and electrocardiograms. Researchers will measure confirmed objective response rates up to about 22 months, and additional outcomes such as progression-free survival, duration of response, adverse events, and changes in clinical and laboratory parameters over about 37 months. Participants are monitored closely for safety and treatment effects throughout their involvement in the trial.

Age: 18Years +All GendersPhase 1Phase 2
85 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are comparing two bowel preparation agents, Lactulose and Sodium Phosphate, to determine which is better for high-quality colonoscopies. This trial is conducted as a randomized, double-blind study involving patients scheduled for outpatient colonoscopy at hospitals in Mexico and Panama between April 1, 2025, and November 30, 2025. The study focuses on colonoscopy quality, patient tolerance, satisfaction, and changes in electrolyte levels. Participants will be randomly assigned to receive either Lactulose or Sodium Phosphate as their bowel preparation on the day they receive their colonoscopy appointment. Both agents are given orally before the procedure. The study excludes patients undergoing emergency or therapeutic colonoscopies and those with specific medical conditions or pregnancy. Data collected include bowel preparation effects and colonoscopy findings, analyzed using statistical software. During the study, participants will undergo assessments such as blood tests to monitor electrolyte changes, evaluation of gastrointestinal side effects, and measures of bowel preparation quality using the Boston Bowel Preparation Scale. Researchers will also assess palatability and adenoma detection rates. Participant data will be securely stored and analyzed to draw conclusions on the best preparation method. The total study period runs from April to November 2025.

Age: 18Years +All GendersPhase 4
4 locations
P

Actively Recruiting

Researchers are evaluating the efficacy of perioperative dostarlimab compared with the standard of care in participants with untreated T4N0 or Stage III resectable colon cancer that shows defective mismatch repair or high microsatellite instability dMMRMSI-H. This phase 3, open-label, randomized study focuses on these specific colon cancer patients to assess if dostarlimab can improve outcomes compared to current treatments. Participants are randomly assigned to receive either dostarlimab before and after surgery or the standard of care treatments, which include FOLFOX or CAPEOX chemotherapy or post-surgery observation. Dostarlimab is given as monotherapy during the perioperative period. The study carefully monitors participants for up to approximately 5 years to evaluate long-term effects. During the trial, participants undergo regular assessments including event-free survival reviewed by blinded independent central review, overall survival, and pathological response evaluations. Safety is closely monitored by tracking adverse events, immune-related effects, and serum concentrations of dostarlimab across treatment cycles. The study involves frequent follow-ups to understand treatment impact and ensure participant well-being throughout the extended observation period.

Age: 18Years +All GendersPhase 3
266 locations